Advertisement

Current Psychiatry Reports

, Volume 14, Issue 2, pp 101–110 | Cite as

Evaluation and Treatment of Children and Adolescents With Psychotic Symptoms

  • Sibel Algon
  • James Yi
  • Monica E. Calkins
  • Christian Kohler
  • Karin E. Borgmann-Winter
CHILD AND ADOLESCENT DISORDERS (TD BENTON, SECTION EDITOR)

Abstract

In recent years, there have been increasing efforts to develop early detection and prevention strategies for patients at risk of the development of psychotic disorders. These efforts have led to improved recognition and characterization of psychotic symptoms in youth. This review focuses on the evaluation of children and adolescents with psychotic symptoms who are experiencing functional impairment but who do not meet current criteria for schizophrenia. For this article, emphasis is placed on the evaluation of symptoms, differential diagnosis, and consideration of potential interventions.

Keywords

Ultra high risk (UHR) Prodrome At-risk Psychosis Psychotic symptoms Children Adolescents Schizophrenia Youth 

Notes

Acknowledgments

Dr. Calkins has received research grant support from the National Institute of Mental Health (K08 Award). Drs. Algon and Yi contributed equally to this manuscript.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gearing, R. E. Evidence-based family psychoeducational interventions for children and adolescents with psychotic disorders. J Can Acad Child Adolesc Psychiatry. 2008;17(1).Google Scholar
  2. 2.
    • Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179–208. In this systematic review, the authors offer a comprehensive overview of available literature on pharmacologic interventions for childhood-onset schizophrenia. The authors summarize limitations in several aspects of current pharmacotherapy, including low effect size, high rates of adverse effects, and low rates of remission. They highlight the need for further research with both randomized, placebo-controlled studies and long-term, naturalistic follow-up of large samples of patients with different age ranges. PubMedCrossRefGoogle Scholar
  3. 3.
    Simon AE, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res. 2006;81(1):83–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Miller TJ, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Klosterkotter J, et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Miller TJ, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Borgmann-Winter K, et al. Assessment of adolescents at risk for psychosis. Curr Psychiatry Rep. 2006;8(4):313–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry. 1998;155(3):325–36.PubMedGoogle Scholar
  9. 9.
    Lax Pericall MT, Taylor E. Psychosis and epilepsy in young people. Epilepsy Behav. 2010;18(4):450–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu HH, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus. 2006;15(10):651–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Bismilla Z, Sell E, Donner E. Hashimoto encephalopathy responding to risperidone. J Child Neurol. 2007;22(7):855–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Arrojo M, et al. Psychiatric presentation of Hashimoto’s encephalopathy. Psychosom Med. 2007;69(2):200–1.PubMedCrossRefGoogle Scholar
  13. 13.
    Benvenga S, Lapa D, Trimarchi F. Don’t forget the thyroid in the etiology of psychoses. Am J Med. 2003;115(2):159–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091.PubMedCrossRefGoogle Scholar
  15. 15.
    Florance NR, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11.PubMedCrossRefGoogle Scholar
  16. 16.
    Fenton KA. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007;45:S213.PubMedCrossRefGoogle Scholar
  17. 17.
    Maling S, et al. HIV-1 seroprevalence and risk factors for HIV infection among first-time psychiatric admissions in Uganda. AIDS Care. 2011;23(2):171–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Scharko AM. DSM psychiatric disorders in the context of pediatric HIV/AIDS. AIDS Care. 2006;18(5):441–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Misdrahi D, et al. DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1). Eur Psychiatry. 2004;19(3):182–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Carman JS, Wyatt RJ. Calcium: pacesetting the periodic psychoses. Am J Psychiatry. 1979;136(8):1035–9.PubMedGoogle Scholar
  21. 21.
    Ang AW, Ko SM, Tan CH. Calcium, magnesium, and psychotic symptoms in a girl with idiopathic hypoparathyroidism. Psychosom Med. 1995;57(3):299–302.PubMedGoogle Scholar
  22. 22.
    Hershko C, et al. Lead poisoning in a West Bank Arab Village. Arch Intern Med. 1984;144(10):1969–73.PubMedCrossRefGoogle Scholar
  23. 23.
    McCracken JT. Lead intoxication psychosis in an adolescent. J Am Acad Child Adolesc Psychiatry. 1987;26(2):274–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Hancu A, Mihai MC, Axelerad AD. Wilson’s disease: a challenging diagnosis. Clinical manifestations and diagnostic procedures in 12 patients. Rev Med Chir Soc Med Nat Iasi. 2011;115(1):58–63.PubMedGoogle Scholar
  25. 25.
    Dening TR, Berrios GE. Wilson’s disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry. 1989;46(12):1126–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Rahman A, et al. Zinc, manganese, calcium, copper, and cadmium level in scalp hair samples of schizophrenic patients. Biol Trace Elem Res. 2009;127(2):102–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lauterbach MD, Stanislawski-Zygaj AL, Benjamin S. The differential diagnosis of childhood- and young adult-onset disorders that include psychosis. J Neuropsychiatry Clin Neurosci. 2008;20(4):409.PubMedCrossRefGoogle Scholar
  28. 28.
    Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-41, HHS Publication No. (SMA) 11-4658, S.A.a.M.H.S. Administration, Editor. 2011: Rockville, MD.Google Scholar
  29. 29.
    Veen ND, et al. Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004;161(3):501–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Dragt S, et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125(1):45–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196–204.PubMedCrossRefGoogle Scholar
  32. 32.
    Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465–88.PubMedCrossRefGoogle Scholar
  33. 33.
    Young CM, Findling RL. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother. 2004;4(1):53–60.PubMedCrossRefGoogle Scholar
  34. 34.
    AACAP official action. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1580–2.CrossRefGoogle Scholar
  35. 35.
    Lubman DI, et al. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. Acta Psychiatr Scand. 2002;106:331.PubMedCrossRefGoogle Scholar
  36. 36.
    Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA. 1999;282(1):36–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Freudenreich O, et al. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. Harv Rev Psychiatry. 2007;15(5):189–211.PubMedCrossRefGoogle Scholar
  38. 38.
    Arseneault L, et al. Childhood trauma and children’s emerging psychotic symptoms: a genetically sensitive longitudinal cohort study. Am J Psychiatry. 2011;168(1):65–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Mazzoni P, et al. Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis. J Child Adolesc Psychopharmacol. 2009;19(6):771–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Meyer SE, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol. 2005;15(3):434–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Velthorst E, et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res. 2009;109(1–3):60–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Woods SW, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study.[see comment]. Schizophr Bull. 2009;35(5):894–908.PubMedCrossRefGoogle Scholar
  43. 43.
    Pavuluri M, Herbener E, Sweeney J. Psychotic symptoms in pediatric bipolar disorder. J Affect Disord. 2004;80:19–28.PubMedCrossRefGoogle Scholar
  44. 44.
    Ulloa RE, et al. Psychosis in a pediatric mood and anxiety disorders clinic: phenomenology and correlates. J Am Acad Child Adolesc Psychiatry. 2000;39(3):337–45.PubMedCrossRefGoogle Scholar
  45. 45.
    Calderoni D, et al. Differentiating childhood-onset schizophrenia from psychotic mood disorders. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1190–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Biederman J, et al. Phenomenology of childhood psychosis: findings from a large sample of psychiatrically referred youth. J Nerv Ment Dis. 2004;192(9):607–14.PubMedCrossRefGoogle Scholar
  47. 47.
    Norman RM, et al. The role of treatment delay in predicting 5-year outcomes in an early intervention program. Psychol Med. 2011;(Journal Article):1–11.Google Scholar
  48. 48.
    Lappin JM, et al. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res. 2007;95(1–3):103–10.PubMedCrossRefGoogle Scholar
  49. 49.
    Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785–804.PubMedCrossRefGoogle Scholar
  50. 50.
    Malla AK, et al. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res. 2011;125(1):13–20.PubMedCrossRefGoogle Scholar
  51. 51.
    McGorry PD, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206–12.PubMedCrossRefGoogle Scholar
  52. 52.
    • Simon AE, et al. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res. 2011;132(1):8–17. This systematic review summarizes available literature on outcomes of those identified as UHR. A total of 31 studies met the inclusion criteria, and on average, 76% (range, 46%–92.6%) of UHR patients made no transition to psychosis during a follow-up period (range, 6–40 months). Characteristics of those who did not transition were poorly investigated. The authors highlight the limited specificity of current UHR criteria and the need for more studies investigating the characteristics associated with nontransition versus transition. PubMedCrossRefGoogle Scholar
  53. 53.
    Filakovic P, et al. Ethics of the early intervention in the treatment of schizophrenia. Psychiatr Danub. 2007;19(3):209–15.PubMedGoogle Scholar
  54. 54.
    McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res. 2001;51(1):47–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Rabinovitch MB-EL, et al. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28.PubMedGoogle Scholar
  56. 56.
    •• de Koning MB, et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand. 2009;119(6):426–42. In this paper, early interventions in patients at UHR for psychosis are reviewed. The authors compiled preliminary publications and unpublished data from the German Research Network on Schizophrenia. Patients from the Bechdolf et al. [58] (2007) cohort who received CBT were found less likely to convert to psychosis or develop a late prodromal state at 1-year follow-up than those who received supportive counseling. PubMedCrossRefGoogle Scholar
  57. 57.
    Addington J, et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54–61.PubMedCrossRefGoogle Scholar
  58. 58.
    Bechdolf A, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry. 2007;1(1):71–8.PubMedCrossRefGoogle Scholar
  59. 59.
    French P, et al. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. Br J Psychiatry Suppl. 2007;51:s82–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Poon MY, Siu AM, Ming SY. Outcome analysis of occupational therapy programme for persons with early psychosis. Work. 2010;37(1):65–70.PubMedGoogle Scholar
  61. 61.
    Rietdijk J, et al. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials. 2010;11:30.PubMedCrossRefGoogle Scholar
  62. 62.
    • Yung AR, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry. 2011;72(4):430–40. The authors conducted a randomized controlled trial in youth at UHR for psychosis comparing CT plus low-dose risperidone with CT, supportive counseling, and a monitoring control condition. All treatment groups had improvements in measures of psychosis and depression, and no differences were found among groups. Declining transition rates, inadequate power, transition post-study, and a placebo effect in the monitoring control condition may explain these findings. PubMedCrossRefGoogle Scholar
  63. 63.
    Morrison AP, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009;17(4):291–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Compton MT, et al. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res. 2011;126(1–3):71–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010;10(8):1347–59.PubMedCrossRefGoogle Scholar
  67. 67.
    •• Liu P, et al. An evidence map of interventions across premorbid, ultra-high risk and first episode phases of psychosis. Schizophr Res. 2010;123(1):37–44. The authors generated an evidence map of controlled trials, meta-analysis, and systematic reviews of biologic and psychosocial interventions in premorbid, UHR, and first-episode patients with psychosis. Most studies in this population involved first-episode patients, antipsychotic medication trials, and CBT trials. The authors concluded that trials of biologic interventions, other than antipsychotics and psychosocial treatments other than CBT, are lacking and are needed in these patients. PubMedCrossRefGoogle Scholar
  68. 68.
    McGlashan TH, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790–9.PubMedCrossRefGoogle Scholar
  69. 69.
    McGorry PD, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Cornblatt BA, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546–57.PubMedCrossRefGoogle Scholar
  71. 71.
    • Amminger GP, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54. The utility of omega-3 PUFAs to diminish the progression of high-risk youth with subthreshold psychotic symptoms to first-episode psychosis was explored in the randomized, placebo-controlled trial. The authors concluded that long-chain omega-3 PUFAs reduce the risk of transition to psychotic disorders and are a safe and well-tolerated prevention strategy in youth with subthreshold psychotic symptoms. PubMedCrossRefGoogle Scholar
  72. 72.
    Woods SW, et al. Glycine treatment of prodromal symptoms, Abstracts of the 5th International Conference on Early Psychosis. Schizophr Res. 2006;86(WC2E):S7.CrossRefGoogle Scholar
  73. 73.
    Liu CC, et al. Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series. Psychiatry Clin Neurosci. 2010;64(2):202–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Woods SW, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl. 2007;51:s96–s101.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sibel Algon
    • 2
  • James Yi
    • 2
  • Monica E. Calkins
    • 3
  • Christian Kohler
    • 3
  • Karin E. Borgmann-Winter
    • 1
    • 2
  1. 1.Center for Neurobiology and Behavior, Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Child and Adolescent Psychiatry Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  3. 3.Neuropsychiatry Section Schizophrenia Research CenterUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations